P4 M01
Alternative Names: P4-M01Latest Information Update: 08 Sep 2026
At a glance
- Originator P4 Microbiome
- Developer D and D Pharmatech; P4 Microbiome
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Peptides
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Periodontal disorders
- Preclinical Inflammatory bowel diseases; Intestinal infections
Most Recent Events
- 20 Aug 2026 Phase-II clinical trials in Periodontal disorders in USA (PO) (D and D Pharmatech pipeline, August 2026)
- 03 Nov 2025 Preclinical development is ongoing in South Korea (P4 Microbiome pipleline, November 2025)
- 26 Dec 2022 Preclinical trials in Intestinal infections in South Korea (unspecified route), prior to December 2022 (P4 Microbiome pipeline, December 2022)